Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00213

Target Information
Type of targetSuccessful target    
DiseaseBacterial infections    [1]
Cancer, unspecific    [2][3]
Human immunodeficiency virus [HIV] disease    [4]
Tumors    [5]
Drug(s)AdenineApprovedDietary shortage[6][7]
AltretamineApprovedOvarian cancer[8]
BleomycinApprovedHodgkin lymphoma[9]
BusulfanApprovedMyeloproliferative disease[10]
CarboplatinApprovedOvarian carcinoma[11]
CarmustineApprovedBrain cancer[12][13]
ChlorambucilApprovedChronic lymphatic leukemia[14]
ClofarabineApprovedAcute lymphoblastic leukemia[16]
ClofazimineApprovedCrohn's disease[17]
DacarbazineApprovedMalignant melanoma[19]
DaunorubicinApprovedAcute myeloid leukemia[20]
Dornase AlfaApprovedCystic fibrosis[21]
Hydroxystilbamidine IsethionateApprovedBlastomycosis[23]
IdoxuridineApprovedHerpes simplex virus infection[24]
LomustineApprovedBrain tumours[26]
MechlorethamineApprovedProstate cancer[27]
MelphalanApprovedMultiple myeloma[28]
MercaptopurineApprovedAcute lymphatic leukemia[29]
MitomycinApprovedGastro-intestinal and breast cancers[32]
Mitomycin AApprovedCancers[33]
Mitomycin CApprovedCancers[20]
NitrofurantoinApprovedUrinary tract infection[35]
OxaliplatinApprovedColorectal cancer[36]
PipobromanApprovedRefractory chronic myeloid leukaemia[38]
ProcarbazineApprovedHodgkin's lymphoma [40]
StreptozocinApprovedMetastatic islet cell carcinoma[42]
TemozolomideApprovedGrade IV astrocytoma [43]
ThioguanineApprovedAcute myeloid leukemia[44]
Uracil mustardApprovedLymphatic malignancies[45]
BalofloxacinLaunchedGram-positive and -negative bacterial infections[46]
Ciprofloxacin XRLaunchedGram-negative bacterial infections[46]
ElsamitrucinPhase IIMantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Advanced Solid Tumors[47]
Abetimus sodiumPhase III teminatedLupus nephritis[48]
GlufosfamideTerminated in Phase IIOvarian cancer[49]
TV-4710Terminated in Phase IISystemic lupus erythematosus[48]
Indol-3-carbinolPreclinicalFungal diseases[50]
Target ValidationClick to Find Target Validation Information.    
Inhibitor2- (3,4-Dihydroxyphenyl)Acetic Acid[51]
Abetimus sodium[48]
Ciprofloxacin XR[46]
Lipid Fragment[51]
Phosphomethylphosphonic Acid Adenosyl Ester[51]
Thiamin Diphosphate[51]
Dornase Alfa[21]
Enediyne antibiotics[20]
IntercalatorActinomycin D[52]
Ethidium bromide[55]
Cis-[PtCl (NH3)2[58]
Methylene blue[60]
Mitomycin A[33]
Mitomycin C[20]
Minor groove binderBisbenzimide (Hoechst 33258)[63]
Di-imidazole lexitropsin[64]
Distamycin A[62]
ModulatorUracil mustard[45]
Hydroxystilbamidine Isethionate[23]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1DNA binding ligands with excellent antibiotic potency against drug-resistant gram-positive bacteria. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2591-4. To Reference
Ref 2DNA-intercalating ligands as anti-cancer drugs: prospects for future design. Anticancer Drug Des. 1989 Dec;4(4):241-63. To Reference
Ref 3Crosslinking of cellular DNA by nitracrine and furocoumarin derivatives. Neoplasma. 1999;46(1):50-3. To Reference
Ref 4Human immunodeficiency virus type 1 (HIV-1) inhibition, DNA-binding, RNA-binding, and ribosome inactivation activities in the N-terminal segments of the plant anti-HIV protein GAP31. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12208-12. To Reference
Ref 5Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003 Nov 1;63(21):7291-300. To Reference
Ref 6E.coli DNA Adenine Methyltransferase: Intra-Site Processivity and Substrate-Induced Dimerization and Activation. Biochemistry. 2009 Jul 6. [Epub ahead of print] To Reference
Ref 7Leishmania donovani singly deficient in HGPRT, APRT or XPRT are viable in vitro and within mammalian macrophages. Mol Biochem Parasitol. 2006 Jul;148(1):24-30. Epub 2006 Mar 15. To Reference
Ref 8Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. Epub 2008 Feb 28. To Reference
Ref 9Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85. To Reference
Ref 10Different behavior of SCE-eliciting lesions induced by low and high doses of busulfan. Environ Mol Mutagen. 2007 Oct;48(8):706-14. To Reference
Ref 11The Xpc gene markedly affects cell survival in mouse bone marrow. Mutagenesis. 2009 Jul;24(4):309-16. Epub 2009 Apr 16. To Reference
Ref 12Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther. 2008 Mar;8(3):343-59. To Reference
Ref 13DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? Cancer Treat Rev. 2008 Oct;34(6):558-67. Epub 2008 May 22. To Reference
Ref 14Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23. Epub 2009 Jun 9. To Reference
Ref 15Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met Ions Biol Syst. 1996;32:641-85. To Reference
Ref 16Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. To Reference
Ref 17Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):241-7. To Reference
Ref 18Intervention of astaxanthin against cyclophosphamide-induced oxidative stress and DNA damage: a study in mice. Chem Biol Interact. 2009 Aug 14;180(3):398-406. Epub 2009 Apr 2. To Reference
Ref 19Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res. 2009 Jun 25. [Epub ahead of print] To Reference
Ref 20Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. To Reference
Ref 21Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45. To Reference
Ref 22Macrococcus brunensis sp. nov., Macrococcus hajekii sp. nov. and Macrococcus lamae sp. nov., from the skin of llamas. Int J Syst Evol Microbiol. 2003 Sep;53(Pt 5):1647-54. To Reference
Ref 23Isolation of giant silk fibroin polysomes and fibroin mRNP particles using a novel ribonuclease inhibitor, hydroxystilbamidine. J Cell Biol. 1980 Oct;87(1):292-6. To Reference
Ref 24Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. To Reference
Ref 25Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water. Environ Sci Pollut Res Int. 2009 Jun 24. [Epub ahead of print] To Reference
Ref 26Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33. To Reference
Ref 27Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62. To Reference
Ref 28A bridging water anchors the tethered 5-(3-aminopropyl)-2'-deoxyuridine amine in the DNA major groove proximate to the N+2 C.G base pair: implications for formation of interstrand 5'-GNC-3' cross-links by nitrogen mustards. Biochemistry. 2008 Jul 8;47(27):7147-57. Epub 2008 Jun 13. To Reference
Ref 296-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202. Epub 2009 Mar 10. To Reference
Ref 30Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9. To Reference
Ref 31Nitroreductase-mediated cell ablation in transgenic zebrafish embryos. Methods Mol Biol. 2009;546:133-43. To Reference
Ref 32Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp Toxicol Pathol. 2009 Jul 14. [Epub ahead of print] To Reference
Ref 33Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem. 2001 Aug 16;44(17):2834-42. To Reference
Ref 34Nelarabine. Drugs. 2008;68(4):439-47. To Reference
Ref 35On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14. To Reference
Ref 36Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Mol Cancer Ther. 2009 Jul;8(7):2015-26. Epub 2009 Jun 30. To Reference
Ref 37Binding of oxamniquine to the DNA of schistosomes. Trans R Soc Trop Med Hyg. 1989 May-Jun;83(3):373-6. To Reference
Ref 38Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12. To Reference
Ref 39Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107. Epub 2007 Jul 1. To Reference
Ref 40Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst). 2009 Jan 1;8(1):72-86. Epub 2008 Oct 21. To Reference
Ref 41Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19. To Reference
Ref 42Hydrodynamics-based Transfection of Pancreatic Duodenal Homeobox 1 DNA Improves Hyperglycemia and is Associated with Limited Complications in Diabetic mice. Endocr J. 2009 Jun 27. [Epub ahead of print] To Reference
Ref 43DNA ligase IV as a new molecular target for temozolomide. Biochem Biophys Res Commun. 2009 Jul 15. [Epub ahead of print] To Reference
Ref 44Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9. Epub 2009 Feb 24. To Reference
Ref 45Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8. To Reference
Ref 46Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. To Reference
Ref 47Spectrum. Product Development Pipeline. 2009. To Reference
Ref 48Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65. To Reference
Ref 49Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. To Reference
Ref 50Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. Epub 2009 May 7. To Reference
Ref 51Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 52Crystallographic analysis of a novel complex of actinomycin D bound to the DNA decamer CGATCGATCG. Biochemistry. 2001 May 15;40(19):5587-92. To Reference
Ref 53Interaction of adriamycin with DNA as studied by resonance Raman spectroscopy. Nucleic Acids Res. 1982 Jun 25;10(12):3803-16. To Reference
Ref 54Interactions of antitumor agents Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA. Biochem Pharmacol. 1985 Dec 15;34(24):4203-13. To Reference
Ref 5531P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12. To Reference
Ref 56Structure, dynamics and hydration of the nogalamycin-d(ATGCAT)2Complex determined by NMR and molecular dynamics simulations in solution. J Mol Biol. 1999 Jul 16;290(3):699-716. To Reference
Ref 57Crystal structure of a covalent DNA-drug adduct: anthramycin bound to C-C-A-A-C-G-T-T-G-G and a molecular explanation of specificity. Biochemistry. 1994 Nov 22;33(46):13593-610. To Reference
Ref 58DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+. Mol Pharmacol. 1998 May;53(5):846-55. To Reference
Ref 59Oral platinum analogue JM216, a radiosensitizer in oxic murine cells. Int J Radiat Biol. 1997 Dec;72(6):675-83. To Reference
Ref 60Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9. Epub 2009 Mar 26. To Reference
Ref 61Naphthyridinomycin-DNA adducts: a molecular modeling study. J Antibiot (Tokyo). 1991 Aug;44(8):885-94. To Reference
Ref 62Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14. To Reference
Ref 63Sequence-dependent effects in drug-DNA interaction: the crystal structure of Hoechst 33258 bound to the d(CGCAAATTTGCG)2 duplex. Nucleic Acids Res. 1994 May 11;22(9):1607-12. To Reference
Ref 64Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G. Structure. 1997 Aug 15;5(8):1033-46. To Reference
Ref 65Drug-DNA binding specificity: binding of netropsin and distamycin to poly(d2NH2A-dT). Biopolymers. 1990;30(1-2):223-7. To Reference
Ref 66Acriflavine binding and DNA stability. Biofizika. 1986 Nov-Dec;31(6):940-3. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543